What are the primary advantages of allylamines over other antifungal classes?
Allylamines uniquely inhibit squalene epoxidase, leading to squalene accumulation and ergosterol depletion, ultimately causing fungal cell death. They are particularly effective and fungicidal against dermatophytes, with a good safety profile, especially for topical applications.
Can you help develop both topical and oral allylamine candidates?
Yes. Our services cover both. For topical candidates, we focus on in vitro skin penetration, retention, and in vivo efficacy in dermatophyte models. For oral candidates, we emphasize systemic bioavailability, metabolic stability, and relevant in vivo infection models.
What types of fungal pathogens do you work with for allylamine research?
We primarily focus on dermatophytes (e.g., Trichophyton floccosum, T. mentagrophytes, Epidermophyton floccosum), but also evaluate activity against Candida species and certain molds depending on the target spectrum of the compound.
What animal models do you utilize for in vivo efficacy studies for allylamines?
For topical allylamines, we utilize established murine or guinea pig models of dermatophytosis (e.g., T. mentagrophytes infection of the skin or nail). For systemic activity, relevant disseminated fungal infection models may be employed.
Do you offer integrated drug discovery programs or just individual assays?
We provide both. You can engage us for specific assays or services (e.g., squalene epoxidase inhibition assay, AST), or we can partner with you on a comprehensive, integrated drug discovery program from hit identification through to preclinical candidate selection.
